Mesa Laboratories Inc. Common Stock (MLAB)

FairStock Score: 40/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Mesa Labs with Graham's demand for a margin of safety and Buffett's preference for durable economics. At the close on 2026-10-13, the stock was $127.56, for a $713.8M market cap. FairStock calculates a P/E of 150.07, P/B of 3.78, Graham Number of $25.40, and margin of safety of -402.20%, so the price is far above current earnings and book value. The turnaround is real: in fiscal 2026, the year ended 2026-03-31, revenue was $249.1M and net income was $6.7M, or $1.21 per diluted share, after fiscal 2025, the year ended 2025-03-31, net loss of $2.0M and fiscal 2024, the year ended 2024-03-31, net loss of $254.2M. In fiscal Q1 2027, the quarter ended 2026-06-30, revenue was $60.1M and net income was $2.8M, or $0.49 per diluted share. Free cash flow is the best feature: $52.9M trailing and a 7.4% FCF yield. But ROE is 2.66%, ROCE is 3.29%, D/E is 0.85, and Altman Z-Score is 1.57. FairStock's Piotroski F-Score of 6/9 and PEG of 0.47 show improvement, and Lynch category is TURNAROUND, but EV/EBITDA of 19.19 is not cheap. With revenue growth modest and profit growth largely a rebound from losses, I see no margin of safety unless margins and leverage improve.

In plain English: Mesa Labs makes testing products and services that help healthcare and life-science customers check whether sterilization and cleaning processes work. The business has swung back to a small profit after large losses, but profits are thin, debt is meaningful, and the shares look expensive compared with current earnings and accounting value. Cash flow is a positive, but the price already seems to assume a lot of improvement.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2027 10-Q (period ended 2026-06-30) · fiscal Q3 2026 10-Q (period ended 2025-12-31) · fiscal Q2 2026 10-Q (period ended 2025-09-30) · fiscal Q1 2026 10-Q (period ended 2025-06-30) · FY2026 10-K (period ended 2026-03-31) · FY2025 10-K (period ended 2025-03-31) · FY2024 10-K (period ended 2024-03-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer